Article Details

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Retrieved on: 2021-07-23 19:41:15

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says. View article details on hiswai:

Excerpt

Now that Alexion's Soliris is in AstraZeneca's hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up